Johnson & Johnson的新药TECVAYLI在治疗多种不产生严重副作用的骨髓瘤方面很有希望。 Johnson & Johnson's new drug TECVAYLI® shows promise in treating multiple myeloma with no severe side effects.

约翰逊公司的新药TECVAYLI®显示出对新诊断多发性骨髓瘤患者的前线治疗有前途. Johnson & Johnson's new drug TECVAYLI® shows promise as a frontline treatment for newly diagnosed multiple myeloma patients. 在研究中,所有病人都取得了最低程度的残余疾病(MRD)的负负性,并在整个治疗过程中保持了这种消极性。 In studies, all patients achieved minimal residual disease (MRD) negativity and maintained it throughout the treatment. 药物一般耐受良好, 尽管一些常见的副作用包括感染和血细胞数量低. The drug was generally well-tolerated, though some common side effects included infections and low blood cell counts. 没有重大不利事件导致终止或死亡。 No severe adverse events led to discontinuation or death.